Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OCRX $5.40 nice article link back and some DD i have posted.
ARWR nice action today, could be due to RGLS with RNAi technology is up huge today. i believe ARWR has same RNAi platform ?
OXGN $2.02 This is finally back on track here over $2. Looks good here.
CNAT- $16 PT -MLV &Co starts at Buy
OCRX $5-bought some more OCRX at $5. This one trades thin and low float. link back for some DD
HEB-Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola
http://finance.yahoo.com/news/hemispherx-announces-strategic-relationship-squire-160000874.html
CNAT 6.94 doing well here. ICPT is also doing well past few days. CNAT trying to break that $7
imo
DARA $0.91 +8% recovering from sell off past few days
CNAT-Presents at AASLD Nov 10 FYI. Late breaker abstract
http://finance.yahoo.com/news/conatus-pharmaceuticals-announces-acceptance-breaking-140000932.html
OCRX- 'Ocera Therapeutics Finally Ready To Reward Investors'- SA article few days ago.. Link back for catalysts
http://seekingalpha.com/article/2534275-ocera-therapeutics-finally-ready-to-reward-investors
Nice article.
ICPT-CNAT-OCRX - My liver disease play all looking good here. OCRX and CNAT low floater could move up quickly imo
MYRY 0.01 ebola tracking news this am nice dip
imo
MYRY $0.01 Ebola tracking news this am. nice dip
MYRY 0.01 Ebola play nice dip and nice news this am.
OCRX - Another live disease play added some here.
CNAT $6.50 added here, they're presenting late breaker abstract at AASLD.. ICPT is showing relative strength as well in this red day.
0.03-0.05 possible HUGE new imo
MYRY $0.015 Ebola tracking news this am. i think huge new
imo only
CERS-The decades-old treatment that may save a young Dallas nurse infected with Ebola
"Injecting the blood of a patient such as Brantly, who has recovered from Ebola and developed certain antibodies, is a decades-old but promising method of treatment that, academics and health officials agree, could be one of the best means to fight Ebola. Called a convalescent serum, it might also save Pham, an alum of Texas Christian University."
http://www.washingtonpost.com/news/morning-mix/wp/2014/10/14/the-decades-old-treatment-that-may-save-a-young-dallas-nurse-infected-with-ebola/
CERS- wedbush thinks "Cerus is in early but accelerating talks with the Gates Foundation that could allow the company's pathogen inactivation system to help enable the use of plasma transfusions as an Ebola treatment . Wedbush keeps a $6.50 price target and Outperform rating on Cerus."
http://www.theflyonthewall.com/permalinks/entry.php/CERSid2078215/CERS-Cerus-risk-reduced-by-Ebola-outbreak--says-Wedbush
That's pretty huge if they're doing this.. we may see LAKE type of move here if they in fact come up for ebola treatment.
imo
LAKE- CNN money had a article yesterday if you want to read here:
http://money.cnn.com/2014/10/09/investing/lakeland-hazmat-suits-ebola/
LAKE only shipped 276 suits to liberia per their blog on sept 26 ?
As the aid response to the Ebola outbreak in West Africa continues to increase, Lakeland Industries is proud that Medical Personnel are relying on our ChemMax1 product to protect their workers that are on the front lines of the epidemic.
PCI Global recently shipped 276 Lakeland ChemMax1 suits to Liberia. These suits will be used to protect healthcare workers who are working to assist those who have become infected with this horrible disease. Protecting medical personnel is critical so as to allow more of those infected by Ebola to get into clinics and seek treatment.
http://www.lakeland.com/blog/index/index/cat/news/
DARA added tons of shares at $0.80 on this dramatic pull back with the market sentiment.
DARA $0.89 watch the bottom bounce imo
DARA $0.90 Looks very cheap and trading at cash levels. never thought i would be able to pick up under $1 on this name. Cash level pretty good and market cap is right around the cash level. Market ignoring any other value.
CNAT-Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
SAN DIEGO, Oct. 8, 2014 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT) today announced that its late-breaking abstract was accepted for a poster presentation at The Liver Meeting(R), the annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, November 7-11, 2014. The poster, entitled "Rapid and statistically significant reduction of markers of apoptosis and cell death in subjects with mild, moderate and severe hepatic impairment treated with a single dose of the pan-caspase inhibitor, emricasan," will be presented on Monday, November 10, 2014. The abstract is available at www.aasld.org/.
http://finance.yahoo.com/news/conatus-pharmaceuticals-announces-acceptance-breaking-140000932.html
OXGN-Big catalyst for small company now coming real fast here. Should catch attention any day here. added more yesterday.
CNAT $6.65->Catalysts approaching very fast. link back for all the catalyst here. will be a solid play fourth quarter and first quarter 15 imo.
CNAT $6.30 Potential catalysts Link Back here:
Lots of Upcoming key catalysts:
(1)ACLF-Phase 2b trial results sufficient to inform on Phase 3
opportunity expected by end of 2014
(2) POLT -HCV - SVR Phase 2b - Initial interim results expected in 1H15
(3)NAFLD/NASH Phase 2 -- Phase 2 trial results expected 1Q15
(4)Liver cirrhosis - Phase 2 interim trial expected 2H15
(5) Portal Hypertension - Phase 2 trial results expected 3Q15
More info can be found in the presentation :
http://files.shareholder.com/downloads/AMDA-20JRI1/3474597647x0x779074/23bdaeb6-f711-42d4-9bda-df0fa372a401/140902%20CNAT%20Update.pdf
CNAT-Appoints David T. Hagerty as Executive Vice President, Clinical Development
http://finance.yahoo.com/news/conatus-pharmaceuticals-appoints-david-t-200100064.html
CNAT-$5.99 Added here. Looks cheap here and many upcoming catalysts. imo.
BAXS $0.168--watching for bottom reversal here. This has gone down by big. This used to trade over $1 and now it's trading at $0.168. I am just taking a shot here and we might get a nice bounce here.
imo only.
Current mkt cap is $8.3M.
Company announced to Explore Strategic Alternatives for Its MIS Spine Business last week.
http://finance.yahoo.com/news/baxano-surgical-explore-strategic-alternatives-113000363.html
Also announced some financing:
Baxano Surgical Completes Financing and Continues Streamlined Business Operations
http://finance.yahoo.com/news/baxano-surgical-completes-financing-continues-113000336.html
BAXS $0.14 bottom reversal watch. Financing news yesterday
BAXS $0.14 rock bottom reversal watch..financing news yesterday..
ECYT $7.42 +4.88% trying to breakout here now. Solid catalyst on Saturday.
ECYT- Chardan Capital ($15 PT) Remains Positive on Endocyte (ECYT) into 2014 ESMO Congress
Chardan Capital reaffirms Endocyte (Nasdaq: ECYT) at Buy with a target price of $15 heading into the upcoming 2014 ESMO Congress this weekend.
Analyst Ling Wang noted that Endocyte's presentations will include: the full data from a phase II TARGET trial of vintafolide in the second line NSCLC (an oral presentation during the late breaker session, #LBA40_PR); interim data from a phase I dose-escalation trial of the folic acid-tubulysin small-molecule drug conjugate EC1456 in advanced solid tumors; and subset analysis from the phase II PRECEDENT trial of vintafolide in ovarian cancer.
Wang comments:
* Phase II TARGET trial has met the primary endpoint of PFS – the OS data will be the key focus. Earlier this year, ECYT has reported the topline data from the TARGET trial. The trial met the primary endpoint of PFS (HR 0.75, p-value 0.0696, one-sided test) under the pre-defined threshold of p<0.1 in the combination of vintafolide and docetaxel arm in FR 100% NSCLC patients. We expect the detailed data to be presented at the ESMO conference to include PFS, ORR and more mature OS data (with ~50-60% of the total death events). At the time of the interim analysis, both ORR and OS favor the vintafolide combination arm.
* We expect potential upside at ESMO driven by low investor expectation and potentially impressive OS benefit. Although it is hard to handicap the OS results given the trial was not sufficiently powered for detecting OS signal and various factors that could impact OS even with the PFS benefit, we see an upside potential given the low investor expectation driven by the setback earlier this year (the discontinuation of the phase III PROCEED trial and partner Merck returned vintafolide rights back to ECYT). Additionally, according to our literature search, there seems to be relatively strong correlation between the HR of PFS and the HR of OS in post-frontline NSCLC trials that don’t allow crossover of treatment, Hidekazu S., et al., Asia-Pacific Journal of Clinical Oncology 2014; and Katsuyuki H et al, Lung Cancer 79 (2013) 20–26). Since TARGET trial does not allow crossover post progression, we see a good chance of reporting OS benefit with relative impressive HR and great risk/reward.
http://www.streetinsider.com/Analyst+Comments/Chardan+Capital+Remains+Positive+on+Endocyte+%28ECYT%29+into+2014+ESMO+Congress/9860243.html
ECYT-late breaking abstract presentation at ESMO on saturday FYI. This might be one to watch. Strong cash position. Share may get nice spike if anything positive comes out
imo.
SUPN $8.23Supernus Pharma reaffirms FY14 outlook; on track to become cash flow breakeven by year-end; does not need to raise additional capital to reach profitability
The Company reaffirms that it is on track to become cash flow breakeven by year-end, with a year-end cash balance of $75 million - $85 million.
The Company reaffirms that it does not need to raise additional capital to reach profitability. It expects to be profitable starting in 2014 and beyond.
The Company reaffirms that it expects revenues of approximately $105 million in 2014.
The Company is focused on executing its current strategy as outlined below to maximize shareholder value.
http://finance.yahoo.com/news/supernus-provides-business-201500213.html
OXGN-OXiGENE Initiates Phase 2 Study of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors
http://finance.yahoo.com/news/oxigene-initiates-phase-2-study-200100936.html
OGXI $3.15 added here. They're presenting ESMO 2014. September 26-30. This will get attention imo.